akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347/ob.gyn.rep.2024.500akusherstvo-1999Research ArticleREVIEW ARTICLESНАУЧНЫЕ ОБЗОРЫReviewing the mechanism of action and results of clinical studies on the antifungal drug ibrexafungerpОбзор механизма действия и результатов клинических исследований противогрибкового препарата ибрексафунгерпhttps://orcid.org/0000-0003-1734-3432ТагироваЛ. И.TagirovaL. I.

Лейсан Иршатовна Тагирова, ассистент

кафедра акушерства и гинекологии

450008; ул. Ленина, д. 3; Уфа

Leysan I. Tagirova, MD, Assistant

Department of Obstetrics and Gynecology

450008; 3 Lenin Str.; Ufa

olofb@list.ruhttps://orcid.org/0000-0002-6434-1926ФарвазоваК. Р.FarvazovaK. R.

Камила Разифовна Фарвазова, студент

лечебный факультет

450008; ул. Ленина, д. 3; Уфа

Kamila R. Farvazova, Student

Faculty of General Medicine

450008; 3 Lenin Str.; Ufa

https://orcid.org/0000-0003-3217-6214ВалееваД. Р.ValeevaD. R.

Дания Рустемовна Валеева, студент

450008; ул. Ленина, д. 3; Уфа

Daniia R. Valeeva, Student

450008; 3 Lenin Str.; Ufa

https://orcid.org/0000-0002-0828-527XОрловаМ. Д.OrlovaM. D.

Мария Дмитриевна Орлова, студент

педиатрический факультет

450008; ул. Ленина, д. 3; Уфа

Maria D. Orlova, Student

Faculty of Pediatrics

450008; 3 Lenin Str.; Ufa

https://orcid.org/0009-0004-2954-8456ГубайдуллинИ. А.GubaidullinI. A.

Ирик Азатович Губайдуллин, студент

лечебный факультет

450008; ул. Ленина, д. 3; Уфа

Irik A. Gubaidullin, Student

Faculty of General Medicine

450008; 3 Lenin Str.; Ufa

https://orcid.org/0000-0001-5021-1023ТулябаеваА. М.TulyabaevaA. M.

Аделина Мурадымовна Тулябаева, студент

лечебный факультет

450008; ул. Ленина, д. 3; Уфа

Adelina M. Tulyabaeva, Student

Faculty of General Medicine

450008; 3 Lenin Str.; Ufa

https://orcid.org/0000-0003-2089-3849АбдульмановаА. Р.AbdulmanovaA. R.

Айлина Робертовна Абдульманова, студент

лечебный факультет

450008; ул. Ленина, д. 3; Уфа

Ailina R. Abdulmanova, Student

Faculty of General Medicine

450008; 3 Lenin Str.; Ufa

https://orcid.org/0009-0005-9075-8898ТряпкоР. В.TryapkoR. V.

Руслан Виталиевич Тряпко, ассистент

кафедра акушерства и гинекологии

344022; Нахичеванский переулок, д. 29; Ростов-на-Дону

Ruslan V. Tryapko, MD, Assistant

Department of Obstetrics and Gynecology

344022; 29 Nakhchivansky Lane; Rostov-on-Don

https://orcid.org/0009-0008-9732-252XШелыгинскийД. А.ShelyginskyD. A.

Даниил Алексеевич Шелыгинский, студент

лечебный факультет

460000; ул. Советская, д. 6; Оренбург

Daniil A. Shelyginsky, Student

Faculty of General Medicine

460000; 6 Sovetskaya Str.; Orenburg

https://orcid.org/0009-0002-7703-3989ХанафиеваА. Р.KhanafievaA. R.

Анжелика Романовна Ханафиева, студент

лечебный факультет

460000; ул. Советская, д. 6; Оренбург

Anzhelika R. Khanafieva, Student

Faculty of General Medicine

460000; 6 Sovetskaya Str.; Orenburg

https://orcid.org/0000-0003-0085-2636СеменоваН. Г.SemenovaN. G.

Настасья Генриховна Семенова, студент

лечебный факультет

450008; ул. Ленина, д. 3; Уфа

Nastasia G. Semenova, Student

Faculty of General Medicine

450008; 3 Lenin Str.; Ufa

https://orcid.org/0000-0002-8967-4903ТакиуллинЭ. М.TakiullinE. M.

Эдуард Маратович Такиуллин, студент

лечебный факультет 

450008; ул. Ленина, д. 3; Уфа

Eduard M. Takiullin, Student

Faculty of General Medicine

450008; 3 Lenin Str.; Ufa

ФГБОУ ВО «Башкирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияBashkir State Medical University, Health Ministry of Russian FederationRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияRostov State Medical University, Health Ministry of Russian FederationRussian FederationФГБОУ ВО «Оренбургский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияOrenburg State Medical University, Health Ministry of Russian FederationRussian Federation202406042024182232245Copyright © Tagirova L.I., Farvazova K.R., Valeeva D.R., Orlova M.D., Gubaidullin I.A., Tulyabaeva A.M., Abdulmanova A.R., Tryapko R.V., Shelyginsky D.A., Khanafieva A.R., Semenova N.G., Takiullin E.M., 20242024Тагирова Л.И., Фарвазова К.Р., Валеева Д.Р., Орлова М.Д., Губайдуллин И.А., Тулябаева А.М., Абдульманова А.Р., Тряпко Р.В., Шелыгинский Д.А., Ханафиева А.Р., Семенова Н.Г., Такиуллин Э.М.Tagirova L.I., Farvazova K.R., Valeeva D.R., Orlova M.D., Gubaidullin I.A., Tulyabaeva A.M., Abdulmanova A.R., Tryapko R.V., Shelyginsky D.A., Khanafieva A.R., Semenova N.G., Takiullin E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/1999   Introduction

   Introduction. Vulvovaginal candidiasis is an extremely common pathology of the female genital organs, leading to a long-term recurrent course and multiple complications. Although currently it is widely known about developing antibiotic resistance of bacterial pathogens, it is necessary to remember about similar phenomenon observed in other groups of infectious agents. In this regard, fungal infection also requires development of new therapeutic techniques and medicinal antifungal drugs, such as ibrexafungerp.

   Aim

   Aim: to analyze available publications revealing the mechanism of action, efficacy, antifungal spectrum and results of clinical trials for a new oral antifungal drug ibrexafungerp.

   Materials and Methods

   Materials and Methods. A search for publications in the electronic databases PubMed, eLibrary and ClinicalTrials.gov, published over the last 25 years was conducted using the following keywords in Russian and English: “candidiasis”, “vulvovaginal candidiasis”, “antifungal drugs”, “ibrexafungerp”, “clinical trials”, “mechanism of action”. Articles were assessed according to PRISMA guidelines. The titles and abstracts of identified publications were independently reviewed to retrieve relevant full text studies. After the selection procedure, 46 articles were included in the review.

   Results

   Results. This review provides information on the creation of the drug ibrexafungerp, its mechanism of action, the activity against a relatively wide range of pathogens, as well as the results from 13 ongoing and completed clinical trials in patients with fungal infection.

   Conclusion

   Conclusion. The analysis of ibrexafungerp-related clinical studies showed its good oral bioavailability, high antifungal efficacy, so that its one-day dosage may further eliminate a need for unnecessarily long hospitalization and complex dosing schedules, thereby increasing adherence to therapy and odds for treatment success.

   Введение

   Введение. Вульвовагинальный кандидоз – чрезвычайно распространенная патология женских половых органов, приводящая к длительному рецидивирующему течению и множеству осложнений. Хотя в наши дни широко известно о развитии резистентности бактериальных возбудителей к антибиотикам, не стоит забывать о подобном явлении и у других групп возбудителей инфекций. Так, грибковая инфекция также требует разработки новых терапевтических методик и медикаментозных противогрибковых препаратов, таких как ибрексафунгерп.

   Цель

   Цель: провести анализ литературы, раскрывающей механизм действия, эффективность, противогрибковый спектр и результаты клинических испытаний нового орального противогрибкового препарата ибрексафунгерп.

   Материалы и методы

   Материалы и методы. Проведен поиск публикаций в электронных базах данных PubMed, еLibrary и ClinicalTrials.gov, опубликованных за последние 25 лет. Поиск исследований проводился с использованием следующих ключевых слов на русском и английском языках: «кандидоз», «вульвовагинальный кандидоз», «противогрибковые препараты», «ибрексафунгерп», «клинические испытания», «механизм действия», «candidiasis», «vulvovaginal candidiasis», «antifungal drugs», «ibrexafungerp», «clinical trials», «mechanism of action». Оценка статей проводилась в соответствии с рекомендациями PRISMA. Авторы независимо друг от друга анализировали названия и аннотации идентифицированных публикаций, после чего извлекали полный текст релевантных исследований. После процедуры отбора в обзор было включено 46 статей.

   Результаты

   Результаты. В обзоре представлена информация о создании препарата ибрексафунгерп, его механизм действия, активность относительно широкого спектра возбудителей, а также результаты 13 продолжающихся и завершенных клинических исследований данного препарата у пациентов с грибковой инфекцией.

   Заключение

   Заключение. Проведенный анализ клинических исследований препарата ибрексафунгерп показал, что его хорошая пероральная биодоступность, высокая противогрибковая эффективность и однодневная дозировка в перспективе исключат необходимость в излишне длительной госпитализации и сложных графиках дозирования, тем самым увеличивая приверженность к терапии и вероятность успеха лечения.

кандидозвульвовагинальный кандидозибрексафунгерпинвазивная грибковая инфекцияэхинокандиныазолыcandidiasisvulvovaginal candidiasisibrexafungerpinvasive fungal infectionechinocandinsazolesАвторы заявляют об отсутствии финансовой поддержкиThe authors declare no fundingReferencesWillems H.M.E., Ahmed S.S., Liu J. et al. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020;6(1):27. doi: 10.3390/jof6010027.Willems H.M.E., Ahmed S.S., Liu J. et al. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020;6(1):27. doi: 10.3390/jof6010027.Гинекология: национальное руководство. Под ред. Г.М. Савельевой, Г.Т. Сухих, В.Н. Серова, В.Е. Радзинского, И.Б. Манухина. М.: ГЭОТАР-Медиа, 2022. 1008 с.Gynecology: national guidelines. Eds. G.M. Savelyeva, G.T. Sukhikh, V.N. Serova, V.E. Radzinsky, I.B. Manukhina. [Ginekologiya: nacional'noe rukovodstvo. Pod red. G.M. Savel'evoj, G.T. Suhih, V.N. Serova, V.E. Radzinskogo, I.B. Manuhina]. Moscow: GEOTAR-Media, 2022. 1008 p. (In Russ.).Хамадьянова А.У., Загидулина А.Р., Загретдинова Д.Р. и др. Перспективы исследования микробиома организма человека для лучшего понимания патогенеза рака яичников. Российский вестник акушера-гинеколога. 2023;23(1):39–46. doi: 10.17116/rosakush20232301139.Khamad’yanova A.U., Zagidulina A.R., Zagretdinova D.R. et al. Prospects of human microbiome study for better understanding of ovarian cancer pathogenesis. [Perspektivy issledovaniya mikrobioma organizma cheloveka dlya luchshego ponimaniya patogeneza raka yaichnikov]. Rossiiskii vestnik akushera-ginekologa. 2023;23(1):39–46. (In Russ.). doi: 10.17116/rosakush20232301139.Байрамова Г.Р., Амирханян А.С., Чернова В.Ф. Вульвовагинальный кандидоз: патогенез, диагностика и тактика лечения. Доктор.Ру. 2018;(10):32–6. doi: 10.31550/1727-2378-2018-154-10-32-36.Bairamova G.R., Amirkhanyan A.S., Chernova V.F. Vulvovaginal candidiasis: pathogenesis, diagnosis and treatment strategy. [Vul'vovaginal'nyj kandidoz: patogenez, diagnostika i taktika lecheniya]. https://journaldoctor.ru/. 2018;(10):32–6. (In Russ.). doi: 10.31550/1727-2378-2018-154-10-32-36.Зиганшин А.М., Мулюков А.Р. Механизмы иммунопатологии сепсиса вирусной этиологии при COVID-19. Сибирское медицинское обозрение. 2021;(6):35–43. doi: 10.20333/25000136-2021-6-35-43.Ziganshin A.M., Mulyukov A.R. Immunopathological mechanisms in sepsis of viral etiology in COVID-19. [Mekhanizmy immunopatologii sepsisa virusnoj etiologii pri COVID-19]. Sibirskoe medicinskoe obozrenie. 2021;(6):35–43. (In Russ.). doi: 10.20333/25000136-2021-6-35-43.Зиганшин А.М., Кейдар С.В., Халитова Р.Ш. и др. Вирус папилломы человека: этиология, патогенез, роль и значение в развитии рака шейки матки. Гинекология. 2023;25(1):17–21. doi: 10.26442/20795696.2023.1.202070.Ziganshin A.M., Keidar S.V., Khalitova R.Sh. et al. Human papillomavirus: etiology, pathogenesis, role, and importance in the development of cervical cancer : a review. [Virus papillomy cheloveka: etiologiya, patogenez, rol' i znachenie v razvitii raka shejki matki]. Ginekologiya. 2023;25(1):17–21. (In Russ.). doi: 10.26442/20795696.2023.1.202070.Qin F., Wang Q., Zhang C. et al. Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. Infect Drug Resist. 2018;11:1893–901. doi: 10.2147/IDR.S175588.Qin F., Wang Q., Zhang C. et al. Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. Infect Drug Resist. 2018;11:1893–901. doi: 10.2147/IDR.S175588.Je N.K., Youm S., Chun P. Real world co-prescribing contraindicated drugs with fluconazole and itraconazole. Pharmacoepidemiol Drug Saf. 2023;32(7):752–62. doi: 10.1002/pds.5604.Je N.K., Youm S., Chun P. Real world co-prescribing contraindicated drugs with fluconazole and itraconazole. Pharmacoepidemiol Drug Saf. 2023;32(7):752–62. doi: 10.1002/pds.5604.Аполихина И.А., Байрамова Г.Р., Гомберг М.А. и др. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.: Российское общество акушеров-гинекологов, 2019. 57 с.Apolikhina I.A., Bairamova G.R., Gomberg M.A. et al. Clinical guidelines for the diagnosis and treatment of diseases accompanied by pathological discharge from femal genital tract. [Klinicheskie rekomendacii po diagnostike i lecheniyu zabolevanij, soprovozhdayushchihsya patologicheskimi vydeleniyami iz polovyh putej zhenshchin]. Moscow: Rossijskoe obshchestvo akusherov-ginekologov, 2019. 57 p. (In Russ.).Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933.Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933.Collins L.M., Moore R., Sobel J.D. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans. J Low Genit Tract Dis. 2020;24(1):48–52. doi: 10.1097/LGT.0000000000000496.Collins L.M., Moore R., Sobel J.D. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans. J Low Genit Tract Dis. 2020;24(1):48–52. doi: 10.1097/LGT.0000000000000496.Babic M., Hukic M. Candida albicans and non-albicans species as etiological agent of vaginitis in pregnant and non-pregnant women. Bosn J Basic Med Sci. 2010;10(1):89–97. doi: 10.17305/bjbms.2010.2744.Babic M., Hukic M. Candida albicans and non-albicans species as etiological agent of vaginitis in pregnant and non-pregnant women. Bosn J Basic Med Sci. 2010;10(1):89–97. doi: 10.17305/bjbms.2010.2744.Mikamo H., Sato Y., Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother. 2000;4Mikamo H., Sato Y., Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother. 2000;46(3):485–7. doi: 10.1093/jac/46.3.485.Denning D.W. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–51. doi: 10.1016/S0140-6736(03)14472-8.Denning D.W. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–51. doi: 10.1016/S0140-6736(03)14472-8.Peláez F., Cabello A., Platas G. et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol. 2000;23(3):333–43. doi: 10.1016/s0723-2020(00)80062-4.Peláez F., Cabello A., Platas G. et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol. 2000;23(3):333–43. doi: 10.1016/s0723-2020(00)80062-4.Onishi J., Meinz M., Thompson J. et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000;44(2):368–77. doi: 10.1128/AAC.44.2.368-377.2000.Onishi J., Meinz M., Thompson J. et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000;44(2):368–77. doi: 10.1128/AAC.44.2.368-377.2000.Apgar J.M., Wilkening R.R., Parker D.L. et al. Ibrexafungerp: an orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021;32:127661. doi: 10.1016/j.bmcl.2020.127661.Apgar J.M., Wilkening R.R., Parker D.L. et al. Ibrexafungerp: an orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021;32:127661. doi: 10.1016/j.bmcl.2020.127661.Davis M.R., Donnelley M.A., Thompson G.R. Ibrexafungerp: a novel oral glucan synthase inhibitor. Med Mycol. 2020;58(5):579–92. doi: 10.1093/mmy/myz083.Davis M.R., Donnelley M.A., Thompson G.R. Ibrexafungerp: a novel oral glucan synthase inhibitor. Med Mycol. 2020;58(5):579–92. doi: 10.1093/mmy/myz083.SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis. Режим доступа: https://ir.scynexis.com/news-events/press-releases/detail/314/scynexis-announces-fda-approval-of-second-indication-for. [Дата обращения: 01. 05. 2023].SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis. Available at: https://ir.scynexis.com/news-events/press-releases/detail/314/scynexis-announces-fda-approval-of-second-indication-for. [Accessed: 01. 05. 2023].Garcia-Rubio R., de Oliveira H.C., Rivera J., Trevijano-Contador N. et al. The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. Front Microbiol. 2020;10:2993. doi: 10.3389/fmicb.2019.02993.Garcia-Rubio R., de Oliveira H.C., Rivera J., Trevijano-Contador N. et al. The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. Front Microbiol. 2020;10:2993. doi: 10.3389/fmicb.2019.02993.Ghannoum M., Arendrup M.C., Chaturvedi V.P. et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel). 2020;9(9):539. doi: 10.3390/antibiotics9090539.Ghannoum M., Arendrup M.C., Chaturvedi V.P. et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel). 2020;9(9):539. doi: 10.3390/antibiotics9090539.Hu X., Yang P., Chai C. et al. Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1. Nature. 2023;616(7955):190–8. doi: 10.1038/s41586-023-05856-5.Hu X., Yang P., Chai C. et al. Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1. Nature. 2023;616(7955):190–8. doi: 10.1038/s41586-023-05856-5.Xie J.L., Grahl N., Sless T. et al. Signaling through Lrg1, Rho1 and Pkc1 governs Candida albicans morphogenesis in response to diverse cues. PLoS Genet. 2016;12(10):e1006405. doi: 10.1371/journal.pgen.1006405.Xie J.L., Grahl N., Sless T. et al. Signaling through Lrg1, Rho1 and Pkc1 governs Candida albicans morphogenesis in response to diverse cues. PLoS Genet. 2016;12(10):e1006405. doi: 10.1371/journal.pgen.1006405.Latgé J.P. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol. 2007;66(2):279–90. doi: 10.1111/j.1365-2958.2007.05872.x.Latgé J.P. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol. 2007;66(2):279–90. doi: 10.1111/j.1365-2958.2007.05872.x.Scorneaux B., Angulo D., Borroto-Esoda K. et al. SCY-078 is fungicidal against Candida species in time-kill studies. Antimicrob Agents Chemother. 2017;61(3):e01961–16. doi: 10.1128/AAC.01961-16.Scorneaux B., Angulo D., Borroto-Esoda K. et al. SCY-078 is fungicidal against Candida species in time-kill studies. Antimicrob Agents Chemother. 2017;61(3):e01961–16. doi: 10.1128/AAC.01961-16.Ghannoum M., Long L., Larkin E.L. et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive Aspergillosis. Antimicrob Agents Chemother. 2018;62(6):e00244–18. doi: 10.1128/AAC.00244-18.Ghannoum M., Long L., Larkin E.L. et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive Aspergillosis. Antimicrob Agents Chemother. 2018;62(6):e00244–18. doi: 10.1128/AAC.00244-18.Park S., Kelly R., Kahn J.N. et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49(8):3264-73. doi: 10.1128/AAC.49.8.3264-3273.2005.Park S., Kelly R., Kahn J.N. et al. Specific substitutions in the echino-candin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49(8):3264-73. doi: 10.1128/AAC.49.8.3264-3273.2005.Marcos-Zambrano L.J., Gómez-Perosanz M., Escribano P. et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017;72(7):1969–76. doi: 10.1093/jac/dkx010.Marcos-Zambrano L.J., Gómez-Perosanz M., Escribano P. et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017;72(7):1969–76. doi: 10.1093/jac/dkx010.Garcia-Effron G., Lee S., Park S. et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53(9):3690–9. doi: 10.1128/AAC.00443-09.Garcia-Effron G., Lee S., Park S. et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53(9):3690–9. doi: 10.1128/AAC.00443-09.Schell W.A., Jones A.M., Borroto-Esoda K. et al. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):e01102–17. doi: 10.1128/AAC.01102-17.Schell W.A., Jones A.M., Borroto-Esoda K. et al. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):e01102–17. doi: 10.1128/AAC.01102-17.Pfaller M.A., Messer S.A., Rhomberg P.R. et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother. 2017;61(8):e00161–17. doi: 10.1128/AAC.00161-17.Pfaller M.A., Messer S.A., Rhomberg P.R. et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother. 2017;61(8):e00161–17. doi: 10.1128/AAC.00161-17.Berkow E.L., Angulo D., Lockhart S.R. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017;61(7):e00435–17. doi: 10.1128/AAC.00435-17.Berkow E.L., Angulo D., Lockhart S.R. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017;61(7):e00435–17. doi: 10.1128/AAC.00435-17.Zhu Y.C., Barat S.A., Borroto-Esoda K. et al. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922. doi: 10.1016/j.ijantimicag.2020.105922.Zhu Y.C., Barat S.A., Borroto-Esoda K. et al. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922. doi: 10.1016/j.ijantimicag.2020.105922.Jiménez-Ortigosa C., Paderu P., Motyl M.R., Perlin D.S. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother. 2014;58(2):1248–51. doi: 10.1128/AAC.02145-13.Jiménez-Ortigosa C., Paderu P., Motyl M.R., Perlin D.S. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother. 2014;58(2):1248–51. doi: 10.1128/AAC.02145-13.Astvad K.M.T., Hare R.K., Arendrup M.C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin Microbiol Infect. 2017;23(11):882–7. doi: 10.1016/j.cmi.2017.03.023.Astvad K.M.T., Hare R.K., Arendrup M.C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin Microbiol Infect. 2017;23(11):882–7. doi: 10.1016/j.cmi.2017.03.023.Pfaller M.A., Messer S.A., Motyl M.R. et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013;57(2):1065–8. doi: 10.1128/AAC.01588-12.Pfaller M.A., Messer S.A., Motyl M.R. et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013;57(2):1065–8. doi: 10.1128/AAC.01588-12.Lamoth F., Alexander B.D. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015;59(7):4308–11. doi: 10.1128/AAC.00234-15.Lamoth F., Alexander B.D. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015;59(7):4308–11. doi: 10.1128/AAC.00234-15.Wring S., Murphy G., Atiee G. et al. Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev. 2019;8(1):60–9. doi: 10.1002/cpdd.588.Wring S., Murphy G., Atiee G. et al. Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev. 2019;8(1):60–9. doi: 10.1002/cpdd.588.Wring S.A., Randolph R., Park S. et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61(4):e02068–16. doi: 10.1128/AAC.02068-16.Wring S.A., Randolph R., Park S. et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61(4):e02068–16. doi: 10.1128/AAC.02068-16.Wring S., Borroto-Esoda K., Solon E., Angulo D. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother. 2019;63(2):e02119–18. doi: 10.1128/AAC.02119-18.Wring S., Borroto-Esoda K., Solon E., Angulo D. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother. 2019;63(2):e02119–18. doi: 10.1128/AAC.02119-18.Lepak A.J., Marchillo K., Andes D.R. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265–72. doi: 10.1128/AAC.04445-14.Lepak A.J., Marchillo K., Andes D.R. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265–72. doi: 10.1128/AAC.04445-14.Spec A., Pullman J., Thompson G.R. et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019;74(10):3056–62. URL: https://pubmed.ncbi.nlm.nih.gov/31304536/..Spec A., Pullman J., Thompson G.R. et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019;74(10):3056–62. URL: https://pubmed.ncbi.nlm.nih.gov/31304536/.Cadet R., Tufa M., Angulo D., Nyirjesy P. A Phase 2b, dose-finding study evaluating oral Ibrexafungerp vs Fluconazole in vulvovaginal candidiasis (DOVE). Obstet Gynecol. 2019;133(1):113S–114S. doi: 10.1097/01.AOG.0000558840.33387.ee.Cadet R., Tufa M., Angulo D., Nyirjesy P. A Phase 2b, dose-finding study evaluating oral Ibrexafungerp vs Fluconazole in vulvovaginal candidiasis (DOVE). Obstet Gynecol. 2019;133(1):113S–114S. doi: 10.1097/01.AOG.0000558840.33387.ee.Goje O., Sobel R., Nyirjesy P. et al. Oral Ibrexafungerp for vulvovaginal candidiasis treatment: an analysis of VANISH 303 and VANISH 306. J Women Health. 2023;32(2):178–86. doi: 10.1089/jwh.2022.0132.Goje O., Sobel R., Nyirjesy P. et al. Oral Ibrexafungerp for vulvovaginal candidiasis treatment: an analysis of VANISH 303 and VANISH 306. J Women Health. 2023;32(2):178–86. doi: 10.1089/jwh.2022.0132.Scynexis SCYNEXIS Announces Positive Top-Line Results from Its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS. Режим доступа: https://ir.scynexis.com/news-events/press-releases/detail/262/scynexis-pivotal-phase-3-vanish-306-trial-results-published. [Дата обращения: 01. 05. 2023].Scynexis SCYNEXIS Announces Positive Top-Line Results from Its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS. Available at: https://ir.scynexis.com/news-events/press-releases/detail/262/scynexis-pivotal-phase-3-vanish-306-trial-results-published. [Accessed: 01. 05. 2023].Phillips N.A., Rocktashel M., Merjanian L. Ibrexafungerp for the treatment of vulvovaginal candidiasis: design, development and place in therapy. Drug Des Devel Ther. 2023;17:363–7. doi: 10.2147/DDDT.S339349.Phillips N.A., Rocktashel M., Merjanian L. Ibrexafungerp for the treatment of vulvovaginal candidiasis: design, development and place in therapy. Drug Des Devel Ther. 2023;17:363–7. doi: 10.2147/DDDT.S339349.

The authors declare that there are no conflicts of interest present.